Pioneering non-viral delivery technologies for in vivo cell and gene therapy
STRM.BIO is developing a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo delivery of genetic medicines, initially focused on rare hematological diseases such as Fanconi anemia and in vivo CAR-T therapies. Our megakaryocyte-derived vesicle (MV) platform is designed to overcome the limitations of viral and synthetic delivery systems, enabling new therapeutic approaches across gene editing, RNA therapeutics, and immune cell engineering.
The MV platform overcomes many of the barriers limiting current viral and synthetic in vivo gene delivery systems. It enables precise, efficient delivery of complex genetic cargos directly to the bone marrow, with the potential for repeat dosing, an important advantage over viral strategies.
By leveraging a single, scalable delivery platform capable of generating multiple therapeutic programs, STRM.BIO is positioned to build a diversified pipeline across indications and modalities from a common technological foundation.
